skip to main content
Language:
Primo Advanced Search
Primo Advanced Search Query Term
Primo Advanced Search prefilters

S03.2 What is the role of quinolone resistance testing in the management of M. genitalium?

Sexually transmitted infections, 2021-07, Vol.97 (Suppl 1), p.A7-A8 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. ;2021 Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1368-4973 ;EISSN: 1472-3263 ;DOI: 10.1136/sextrans-2021-sti.27

Full text available

Citations Cited by
  • Title:
    S03.2 What is the role of quinolone resistance testing in the management of M. genitalium?
  • Author: Murray, G
  • Subjects: Mutation
  • Is Part Of: Sexually transmitted infections, 2021-07, Vol.97 (Suppl 1), p.A7-A8
  • Description: In the wake of escalating macrolide resistance, resistance to fluoroquinolones has emerged as a problem requiring urgent attention. The mechanisms of resistance for macrolides (single nucleotide mutations in the 23S rRNA gene) are well defined both in vitro and clinically through analysis of treatment failure; resistance-guided therapy based on these mutations can achieve first line cure levels of over 90%. This contrasts with our understanding of the mechansims of fluoroquinolone resistance, where multiple single nucleotide polymorphisms in the parC gene have been postulated to contribute, but evidence supporting a role of each mutation is limited. Currently there are a number of commercial assays reporting various mutations linked to fluoroquinolone resistance. This talk will look at the evidence supporting the use of these assays and how these assays may contribute to patient management.
  • Publisher: London: BMJ Publishing Group LTD
  • Language: English
  • Identifier: ISSN: 1368-4973
    EISSN: 1472-3263
    DOI: 10.1136/sextrans-2021-sti.27
  • Source: ProQuest Central

Searching Remote Databases, Please Wait